1-4 of 4
Larry Greenbaum, MD
Close
Sort by
Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Larry Greenbaum, MD, Marc Fila, Gianluigi Ardissino, Samhar Al-Akash, Jonathan Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole Kar, Johan Vande Walle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD
Journal: Blood
Blood (2013) 122 (21): 2191.
https://doi.org/10.1182/blood.V122.21.2191.2191
Published: 2013
Journal Articles

Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.

Larry Greenbaum, MD, Christophe M. Legendre, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Frank Eitner, MD, Yahsou Delmas, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD
Journal: Blood
Blood (2012) 120 (21): 2084.
https://doi.org/10.1182/blood.V120.21.2084.2084
Published: 2012
Journal Articles

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Petra Muus, MD, PhD, Christoph Licht, MD, Tim H. J. Goodship, MD, Larry Greenbaum, MD, Camille L Bedrosian, MD, Chantal Loirat, MD, Christophe Legendre, MD
Journal: Blood
Blood (2011) 118 (21): 4772.
https://doi.org/10.1182/blood.V118.21.4772.4772
Published: 2011
Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study

Larry Greenbaum, MD, Sunil Babu, MD, Richard R. Furman, MD, Neil Sheerin, MD, David Cohen, MD, Osama Gaber, MD, Frank Eitner, MD, Yahsou Delmas, MD, Chantal Loirat, MD, Camille L Bedrosian, MD, Christophe Legendre, MD
Journal: Blood
Blood (2011) 118 (21): 193.
https://doi.org/10.1182/blood.V118.21.193.193
Published: 2011